AstraZeneca PLC ADR (AZN) News

AstraZeneca PLC ADR (AZN): $79.59

0.06 (+0.08%)

POWR Rating

Component Grades








Add AZN to Watchlist
Sign Up

Filter AZN News Items

AZN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AZN News Highlights

  • For AZN, its 30 day story count is now at 20.
  • Over the past 6 days, the trend for AZN's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • GRCL, IONS and CRL are the most mentioned tickers in articles about AZN.

Latest AZN News From Around the Web

Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.

The Big Pharma mainstay is set to deliver double-digit earnings growth, driven by a diverse portfolio of blockbusters and promising newcomers.

Yahoo | December 28, 2023

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Josh Enomoto on InvestorPlace | December 27, 2023

Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.

Yahoo | December 27, 2023

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BM

Yahoo | December 27, 2023

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Yahoo | December 27, 2023

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

Astrazeneca (AZN) has been one of the stocks most watched by users lately. So, it is worth exploring what lies ahead for the stock.

Yahoo | December 27, 2023

Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo | December 27, 2023

16 Most Promising Dividend Stocks According to Analysts

In this article, we discuss 16 most promising dividend stocks according to analysts. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Most Promising Dividend Stocks According to Analysts. This year brought a notable shift in the investment scene, where technology stocks surged […]

Yahoo | December 27, 2023

PRESS DIGEST-British Business - Dec 27

The following are the top stories on the business pages of British newspapers. - AstraZeneca has struck a $1.2 billion deal to buy Gracell Biotechnologies, a Chinese company that creates innovative treatments for cancer and rare autoimmune diseases. - EasyPark Group, the owner of brands including RingGo and ParkMobile, said customer names, phone numbers, addresses, email addresses and parts of credit card numbers had been taken in a cyberattack but said parking data had not been compromised.

Yahoo | December 27, 2023

AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

AstraZeneca announced Tuesday it would acquire Gracell Biotechnologies in a deal valued at up to $1.2 billion. Gracell is a Chinese biopharmaceutical company that focuses on cancer drug development. AstraZeneca said in a press release that it plans on buying the company to further its cell therapy ambitions.

Yahoo | December 26, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!